We claim:

1. A method of treating a subject who has psoriasis, the method comprising administering a multiple course of treatment of a soluble CD2-binding LFA-3 polypeptide to the subject, wherein the multiple course comprises multiple cycles of treatment, and wherein each cycle comprises an administration period and a rest period.

2. The method of claim 1, wherein the soluble CD2-binding LFA-3 polypeptide is an LFA-3 fusion protein.

3. The method of claim 1, wherein the soluble CD2-binding LFA-3 polypeptide is an LFA-3/immunoglobulin (Ig) fusion protein.

4. The method of claim 1, wherein the soluble CD2-binding LFA-3 polypeptide comprises a soluble LFA-3 polypeptide fused to all or part of an Ig heavy chain hinge region and all or part of a heavy chain constant region.

5. The method of claim 1, wherein the soluble CD2-binding LFA-3 polypeptide comprises a fusion protein consisting of the amino terminal 92 amino acids of mature LFA-3, the C-terminal 10 amino acids of a human IgG1 hinge region, a CH2 region of a human IgG1 heavy chain, and at least part of a CH3 region of a human IgG1 heavy chain.

6. The method of claim 1, wherein the soluble CD2-binding LFA-3 polypeptide is AMEVIVE (Fig. 1).

7. The method of claim 1, wherein the soluble CD2-binding LFA-3 polypeptide is encoded by an insert contained in plasmid pSAB152, deposited with American Type Culture Collection under the accession number ATCC 68720.

8. The method of any one of claims 1-7, wherein the multiple course comprises at least four cycles of treatment.

9. The method of any one of claims 1-7, wherein the multiple course comprises at least five cycles of treatment.

10. The method of any one of claims 1-7, wherein the multiple course comprises at least six cycles of treatment.

11. The method of any one of claims 1-7, wherein the multiple course comprises at least seven cycles of treatment.

12. The method of any one of claims 1-7, wherein the multiple course comprises at least eight cycles of treatment.

13. The method of any one of claims 1-7, wherein the rest period of each successive cycle of the multiple course is longer than the rest period of a previous cycle in the multiple course

14. The method of any one of claims 1-7, wherein the rest period of the last cycle of the multiple course is at least 2 years.

15. The method of any one of claims 1-7, wherein the rest period of the last cycle of the multiple course is at least 3 years.

16. The method of any one of claims 1-7, wherein the administration period of each cycle of the multiple course is at least 8 weeks.

17. The method of any one of claims 1-7, wherein the administration period of each cycle of the multiple course is at least 10 weeks.

18. The method of any one of claims 1-7, wherein the administration period of each cycle of the multiple course is at least 12 weeks.

19. The method of any one of claims 1-7, wherein the polypeptide is administered intramuscularly.

20. The method of any one of claims 1-7, wherein the polypeptide is administered intravenously.

21. The method of any one of claims 1-7, wherein the polypeptide is administered at a unit dosage ranging from 2 to 30 mg.

22. The method of any one of claims 1-7, wherein the method further comprises administering to the subject an additional therapeutic or prophylactic agent during the multiple course of treatment.

23. A method of treating a subject in need of treatment for psoriasis, the method comprising administering a multiple course of treatment of AMEVIVE (Fig. 1) to the subject, wherein the multiple course of treatment comprises at least three cycles of treatment, each cycle of treatment comprising an administration period of once-weekly administration of AMEVIVE (Fig. 1) for 12 weeks, followed by a rest period of at least 12 weeks.

24. The method of claim 23, wherein the multiple course of treatment comprises at least four cycles of treatment.

25. The method of claim 23, wherein the multiple course of treatment comprises at least five cycles of treatment.

26. The method of claim 23, wherein the method comprises evaluating the subject for the effects of AMEVIVE (Fig. 1) during one or both of the administration period and the rest period of each cycle in the multiple course.

27. The method of claim 23, wherein the method further comprises administering to the subject an additional therapeutic or prophylactic agent during the multiple course of treatment.

28. A method of treating a subject having psoriasis, the method comprising (a) selecting a subject on the basis of having had at least two cycles of treatment with a soluble CD2-binding LFA-3 polypeptide and (b) administering a third cycle of treatment of a soluble CD2-binding LFA-3 polypeptide to the subject.

29. The method of claim 28, wherein the soluble CD2-binding LFA-3 polypeptide is AMEVIVE (Fig. 1).

30. A kit comprising a pharmaceutical composition comprising AMEVIVE and instructions to administer the pharmaceutical composition to a patient who has previously had two cycles of treatment with AMEVIVE (Fig. 1).